Eli Lilly To Acquire Merida And Pay Up To $2.875B In Cash; Transaction Expected To Close In Q4 2026
Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune functionInitial Phase 1 data show MER511 achieved robust reductions
Eli Lilly is buying a smaller company called Merida for up to $2.875 billion because Merida has a cool new tool to remove bad antibodies from your body while keeping the good ones safe. This shows Eli Lilly thinks this technology could help make new medicines, so watch to see if their new products work well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.